Hormonal treatment of endometrial stromal sarcomas (ESS): A possible indication for aromatase inhibitors

Tobias Lindner, Peter Reichardt(Helios Hospital Berlin-Buch), Daniel Pink(Universitätsmedizin Greifswald), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), A. Mrozek(Helios Hospital Berlin-Buch), Albrecht Kretzschmar(Roche (Switzerland))

Journal of Clinical Oncology

June 1, 2005

10.1200/jco.2005.23.16_suppl.9057

Cited by 6

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|751

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

|European Journal of Cancer|2019|724